Loading...
Diagnosis and evaluation of prognosis of myelofibrosis: A british society for haematology guideline
McLornan, DP Godfrey, AL Green, A Frewin, R Arami, S Brady, J Butt, NM Cargo, C Ewing, J Francis, S
McLornan, DP
Godfrey, AL
Green, A
Frewin, R
Arami, S
Brady, J
Butt, NM
Cargo, C
Ewing, J
Francis, S
Citations
Altmetric:
Abstract
SUMMARY AND AIMS
This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.
METHODOLOGY
These guidelines were compiled according to the BSH process https://b-s-h.org.uk/media/16732/bsh-guidance-development-process-dec-5-18.pdf. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Recommendations are based on a review of the relevant MF-related literature using Medline, PubMed/Medline and Cochrane searches beginning from 2012 up to mid-2022. Filters were applied to include only publications written in English, studies carried out in humans, clinical conferences, congresses, clinical trials, clinical studies, meta-analyses, multicentre studies and randomised controlled trials. Exclusion criteria included papers published in non-English journals and those publications without an abstract.
REVIEW OF THE MANUSCRIPT
Review of the manuscript was performed by the BSH Guidelines Committee Haemato-oncology Task Force, the BSH Guidelines Committee and the Haemato-oncology sounding board of the BSH. We invited two global expert external reviewers to review contents—Professor Ruben Mesa and Professor Alessandro Vannucchi. This guideline has also been reviewed by patient representatives from MPN Voice.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
McLornan DP, Godfrey AL, Green A, Frewin R, Arami S, Brady J, et al. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline. British journal of haematology. 2023 Nov 6. PubMed PMID: 37932932. Epub 2023/11/07. eng.